BeyondSpring Inc. (BYSI) Form 8-K — Sep 29, 2026
BeyondSpring entered a Share Purchase and Collaboration Agreement to sell BeyondSpring Ltd. (which holds its majority stake in China subsidiary Bulin) to Biolin Investment Limited for no cash consideration. The non-cash consideration is Biolin's obligation to complete the China portion of the DUBLIN-4 Phase 3 Plinabulin trial over a three-year enrollment period, with partial or full equity clawback if enrollment targets are missed. BeyondSpring retains an exclusive perpetual royalty-free license to all China trial data to support its global Plinabulin registration strategy.
Key figures
- Shares Offered
- 9200000
- Commission Rate
- up to 3.0%
- Floor Price
- $1.00 per share minimum without agent consent
- Enrollment period years
- 3
- Enrollment shortfall threshold
- 90% shortfall requires return of 100% of Equity Interests
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.